More than 3.1 million American men are currently living with prostate cancer. An improved PET/CT scan could also mean an improved prostate cancer treatment plan, which is why ADR now offers PSMA PET/CT scans using Pylarify®.

A PSMA PET/CT is a new imaging technique used to locate cancerous lesions. PSMA stands for Prostate-Specific Membrane Antigen which is essentially a protein that is found mainly on prostate cancer cells.  The radioactive tracer is injected and attaches to PSMA proteins. When a whole body scan is performed,  the concentrated PSMA tracer is detected and pinpoints the tumors for more effective treatment.

PYLARIFY® is a diagnostic imaging agent used in conjunction with PET/CT scans to find tumors in the prostate, lymph nodes, bones, and other organs.  PYLARIFY® uses a radioactive tracer called fluorine-18 that attaches to prostate-specific membrane antigen (PSMA), a protein found on the surface of most prostate cancer cells. By targeting PSMA, PYLARIFY® can give your doctor a clearer image and  information on the location and the extent of the cancer.

Those with suspected metastasis who are candidates for initial definitive therapy and those with suspected recurrence based on elevated PSA levels are best suited for this exam.